...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 and Enzalutamide 2b Trial

Thanks RVXOT. I am happy to see that the Phase 2b clinical development of ZEN-3694 + enzalutamide in mCRPC is proceeding, one way or another. Personally I would rather it be a US based trial with Astellas rather than a China based Newsoara trial. So if the plans for the latter are delayed or no longer planned, so be it as long as the Astellas trial proceeds.

BDAZ 

Share
New Message
Please login to post a reply